Global survey of current practice in management of hypertension as reported by societies affiliated with the international society of hypertension
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: The International Society of Hypertension (ISH) surveyed trends in the management of hypertension worldwide, as reported by its affiliated societies. METHODS: A formal questionnaire was emailed in December 2011 to 90 national and regional societies affiliated with the ISH, from 77 countries. Responses received by June 2012 were analysed. RESULTS: Thirty-one societies responded (nine high-income, 17 upper-middle-income, five lower-middle/low-income countries). Twenty-one reported use of national guidelines, three used regional and 17 used 'international guidelines', two-thirds used mercury, aneroid and semi-automatic sphygmomanometers and half used ambulatory blood pressure monitoring. Exercise, salt restriction and weight reduction were recommended by 31, 27 and 26 nations, respectively, but less for other diets, smoking cessation and alcohol restriction. Almost all nations used angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), calcium channel blockers and diuretics. β Blockers were only recommended for patients with coronary disease. ACEI and ARB were preferred for patients with diabetes, renal disease and metabolic syndrome. Combination treatment was recommended by all, for initiation of treatment by most, and in fixed-dose formulation by half. Most used a threshold of 140/90 mmHg to initiate drug treatment in uncomplicated patients but only half retained the threshold of 130/80 mmHg for high-risk patients. Differences in treatment patterns across regions or across high, middle and low-income countries were minimal. CONCLUSION: There was surprising consistency across countries from different regions and with varying degrees of affluence. There was a trend towards more conservative thresholds and targets than those recommended by JNC7 or ESH/ESC 2007. Combination therapy was favoured by all, but β blockers were restricted to patients with coronary heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“yet only about half of hypertension guidelines worldwide recommend a reduction in alcohol consumption to reduce raised blood pressure.62”
From The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis (2017) · cites this paper as [62]
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
(2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,672
US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008
Egan, B. M. (2010) · JAMA · doi:10.1001/jama.2010.650 · Cited by 2,197
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065
Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M. J., Cifkova, R., Clément, D., Coca, A., Dominiczak, A., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e328333146d · Cited by 1,643
on behalf of The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension, Ogihara, T., Kikuchi, K., Matsuoka, H., Fujita, T., Higaki, J., Horiuchi, M., Imai, Y., Imaizumi, T., Ito, S., et al. (2014) · Hypertension Research · doi:10.1038/hr.2014.68 · Cited by 1,385
Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis
Lindholm, L. H., Carlberg, B., & Samuelsson, O. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67573-3 · Cited by 999
Cutler, J. A., Sorlie, P. D., Wolz, M., Thom, T., Fields, L. E., & Roccella, E. J. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.113357 · Cited by 917
Cooper-DeHoff, R. M., Gong, Y., Handberg, E. M., Bavry, A. A., Denardo, S. J., Bakris, G. L., & Pepine, C. J. (2010) · JAMA · doi:10.1001/jama.2010.884 · Cited by 651
on behalf of The Japanese Society of Hypertension Committee, Ogihara, T., Kikuchi, K., Matsuoka, H., Fujita, T., Higaki, J., Horiuchi, M., Imai, Y., Imaizumi, T., Ito, S., et al. (2009) · Hypertension Research · doi:10.1038/hr.2009.34 · Cited by 486
Management of hypertension: summary of NICE guidance
Krause, T., Lovibond, K., Caulfield, M., McCormack, T., Williams, B., & on behalf of the Guideline Development Group (2011) · BMJ · doi:10.1136/bmj.d4891 · Cited by 477
Sleight, P., Redon, J., Verdecchia, P., Mancia, G., Gao, P., Fagard, R., Schumacher, H., Weber, M., Böhm, M., Williams, B., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832d7370 · Cited by 352
Level of Systolic Blood Pressure Within the Normal Range and Risk of Recurrent Stroke
Ovbiagele, B., Diener, H.-C., Yusuf, S., Martin, R. H., Cotton, D., Vinisko, R., Donnan, G. A., Bath, P. M., & PROFESS Investigators, F. T. (2011) · JAMA · doi:10.1001/jama.2011.1650 · Cited by 248
on behalf of the COLM study investigators, Ogihara, T., Saruta, T., Rakugi, H., Shimamoto, K., Ito, S., Matsuoka, H., Horiuchi, M., Imaizumi, T., Takishita, S., et al. (2009) · Hypertension Research · doi:10.1038/hr.2008.31 · Cited by 169
Latin American guidelines on hypertension*
Sanchez, R. A., Ayala, M., Baglivo, H., Velazquez, C., Burlando, G., Kohlmann, O., Jimenez, J., Jaramillo, P. L., Brandao, A., Valdes, G., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832aa6d2 · Cited by 119
Prugger, C., Keil, U., Wellmann, J., Bacquer, D. D., Backer, G. D., Ambrosio, G. B., Reiner, Ž., Gaiță, D. I., Wood, D., Kotseva, K., et al. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e328348efa7 · Cited by 100
Meng, X.-J., Dong, G., Wang, D., Liu, M.-M., Lin, Q., Tian, S., Xu, L., Hou, H., Ren, Y.-F., & Lee, Y. L. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e328347f79e · Cited by 95
Prince, M. J., Ebrahim, S., Acosta, D., Ferri, C. P., Guerra, M., Huang, Y., Jacob, K. S., Jimenez-Velazquez, I. Z., Rodriguez, J. L., Salas, A., et al. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834d9eda · Cited by 88
Catalá-López, F., Sanfélix‐Gimeno, G., García-Torres, C., Ridao-López, M., & Peiró, S. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834d30ec · Cited by 67
Is a Blood Pressure Target of <130/80 mm Hg Still Appropriate for High-Risk Patients?
Chalmers, J. P. (2011) · Circulation · doi:10.1161/circulationaha.111.057091 · Cited by 16
Self-citation
Research works printed but not linked: 2
- Carlberg, 2004, Atenolol in hypertension: is it a wise choice L, ancet, 364, 1684
- Messerli, 2009, The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential J Am Coll C, ardiol, 54, 1827
Cited by
Huynh, K., Bernardo, B. C., McMullen, J. R., & Ritchie, R. H. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.01.003 · Cited by 553
Roerecke, M., Kaczorowski, J., Tobe, S. W., Gmel, G., Hasan, O. S. M., & Rehm, J. (2017) · The Lancet Public Health · doi:10.1016/s2468-2667(17)30003-8 · Cited by 552
Effects of Blood Pressure Reduction in Mild Hypertension: A Systematic Review and Meta-analysis
Sundström, J., Arima, H., Jackson, R., Turnbull, F., Rahimi, K., Chalmers, J., Woodward, M., Neal, B., & on behalf of the Blood Pressure Lowering Treatment Trialists' Collaboration* (2015) · Annals of Internal Medicine · doi:10.7326/m14-0773 · Cited by 262
Self-citationRehan, H. S., Grover, A., & Hungin, A. P. S. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0715-4 · Cited by 9
Metadata
- Authors
- Chalmers, J., Arima, H., Harrap, S., Touyz, R. M., & Park, J. B.
- Affiliations
- The University of Sydney (AU)
- The University of Melbourne (AU)
- University of Glasgow (GB)
- Cheil General Hospital and Women's Healthcare Center (KR)
- Corresponding author
- Chalmers, John
- Venue
- Journal of Hypertension
- Published
- 2013-05
- Volume
- 31
- Issue
- 5
- Pages
- 1043-1048
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W2076440579
- Cited by
- 43
- References
- 24
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 4 · 2018: 6 · 2017: 3 · 2016: 4 · 2015: 1 · 2014: 13 · 2013: 5
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hypertension (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- World Bank Group
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- antihypertensive therapy, clinical practice patterns, blood pressure targets, combination therapy, ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics, beta-blockers, ambulatory blood pressure monitoring, salt restriction, physical activity, weight loss, smoking cessation, alcohol restriction, diabetes mellitus, kidney disease, metabolic syndrome, coronary artery disease
- MeSH terms
- Adrenergic beta-Antagonists, Angiotensin-Converting Enzyme Inhibitors, Calcium Channel Blockers, Cross-Sectional Studies, Data Collection, Drug Therapy, Combination, Humans, Hypertension, Surveys and Questionnaires, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.